Lipid-based nanocarriers for CNS-targeted drug delivery

Recent Patents on CNS Drug Discovery

Volumn 7, Issue 1, 2012, Pages 71-86

  Micheli, Maria Rita ^a   Bova, Rodolfo ^a   Magini, Alessandro ^a   Polidoro, Mario ^a   Emiliani, Carla ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Blood brain barrier; CNS; Drug delivery; Gene delivery; Liposome; Micelle; Nanocapsule; Nanocarrier; Targeting

Indexed keywords

BOROCAPTATE; CENTRAL NERVOUS SYSTEM AGENTS; DOXORUBICIN; LIPID; LIPOSOME; N,N,N TRIMETHYLTEMPAMINE; NANOCAPSULE; NANOCARRIER; OLIGONUCLEOTIDE; RIVASTIGMINE; TOPOTECAN;

BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; CHEMICAL COMPOSITION; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG PENETRATION; DRUG RELEASE; DRUG SOLUBILITY; DRUG STABILITY; GENE TARGETING; HUMAN; LIGAND BINDING; MICELLE; NANOTECHNOLOGY; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; REVIEW;

ANIMALS; CENTRAL NERVOUS SYSTEM AGENTS; CENTRAL NERVOUS SYSTEM DISEASES; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; LIPOSOMES; NANOTECHNOLOGY;

EID: 84857423416     PISSN: 15748898     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488912798842241     Document Type: Review

References (192)

1. Begley DJ. Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. Pharmacol Ther 2004; 104: 29-45.
2. Chen Y, Dalwadi G, Benson HAE. Drug delivery across the bloodbrain barrier. Curr Drug Deliv 2004; 1: 361-76.
3. Pardridge WM. The blood-brain barrier: bottleneck in brain drug development. NeuroRx 2005; 2: 3-14.
4. de Boer AG, Gaillard PJ. Drug targeting to the brain. Annu Rev Pharmacol Toxicol 2007; 47: 323-55.
5. Pardridge WM. Blood-brain barrier delivery. Drug Discov Today 2007; 12: 54-61.
6. Nag S. Morphology and molecular properties of cellular components of normal cerebral vessels. In: Nag S, editor. The blood-brain barrier: biology and research protocols. Totowa (NJ): Humana Press; 2003. P. 3-36. (Methods in Molecular Medicine; vol 89).
7. Bernacki J, Dobrowolska A, Nierwinska K, Maecki A. Physiology and pharmacological role of the blood-brain barrier. Pharmacol Rep 2008; 60: 600-22.
8. Alam MI, Beg S, Samad A, Baboota S, Kohli K, Ali J, et al. Strategy for effective brain drug delivery. Eur J Pharm Sci 2010; 40: 385-403.
9. Yang H. Nanoparticle-mediated brain-specific drug delivery, imaging and diagnosis. Pharm Res 2010; 27: 1759-71.
10. Fernandes C, Soni U, Patravale V. Nano-intervention for neurodegenerative disorders. Pharmacol Res 2010; 62: 166-78.
11. Perez-Martinez FC, Guerra J, Posadas I, Ceña V. Barriers to nonviral vector-mediated gene delivery in the nervous system. Pharm Res 2011; 28: 1843-58.
12. Brambilla D, Le Droumaguet B, Nicolas J, Hashemi SH, Wu LP, Moghimi SM, et al. Nanotechnologies for Alzheimer's Disease: diagnosis, therapy, and safety issues. Nanomedicine 2011; doi:10.1016/j.nano2011.03.008.
13. Modi G, Pillay V, Choonara YE. Advances in the treatment of neurodegenerative disorders employing nanotechnology. Ann N Y Acad Sci 2010; 1184: 154-72.
14. Bhaskar S, Tian F, Stoeger T, Kreyling W, de la Fuente JM, Grazú V et al. Multifunctional Nanocarriers for diagnostics, drug delivery and targeted treatment across blood-brain barrier: perspectives on tracking and neuroimaging. Part Fibre Toxicol 2010; 7: 3-27.
15. Sahni JK, Doggui S, Ali J, Baboota S, Dao L, Ramassamy C. Neurotherapeutic applications of nanoparticles in Alzheimer's disease. J Control Release 2011; 152: 208-31.
16. Laquintana V, Trapani A, Denora N, Wang F, Gallo JM, Trapani G. New strategies to deliver anticancer drugs to brain tumors. Expert Opin Drug Deliv 2009; 6: 1017-32.
17. Roger M, Clavreul A, Venier-Julienne MC, Passirani C, Montero-Menei C, Menei P. The potential of combinations of drug-loaded nanoparticle systems and adult stem cells for glioma therapy. Biomaterials 2011; 32: 2106-16.
18. Tiwari SB, Amiji MM. A review of nanocarrier-based CNS delivery systems. Curr Drug Deliv 2006; 3: 219-32.
19. Gabizon AA, Shmeeda H, Zalipsky S. Pros and cons of the liposome platform in cancer drug targeting. J Liposome Res 2006; 16:175-83.
20. Gradishar WJ. Albumin-bound paclitaxel: a next-generation taxane. Expert Opin Pharmacother 2006; 7:1041-53.
21. Danson S, Ferry D, Alakhov V, Margison J, Kerr D, Jowle D, et al. Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer. Br J Cancer 2004; 90: 2085-91.
22. Armstrong A, Brewer J, Newman C, Alakhov V, Pietrzynski G, Campbell S, et al. SP1049C as first-line therapy in advanced (inoperable or metastatic) adenocarcinoma of the oesophagus: a phase II window study. J Clin Oncol 2006; 24: 4080.
23. Matsumura Y. Micelle carrier system in clinical trial. Nippon Rinsho 2006; 64: 316-21.
24. Lerner EN, van Zanten EH, Stewart GR. Enhanced delivery of octreotide to the brain via transnasal iontophoretic administration. J Drug Target 2004; 12: 273-80.
25. Wu H, Hu K, Jiang X. From nose to brain: understanding transport capacity and transport rate of drugs. Expert Opin Drug Deliv 2008; 5: 1159-68.
26. Mistry A, Stolnik S, Illum L. Nanoparticles for direct nose-to-brain delivery of drugs. Int J Pharm 2009; 379: 146-57.
27. Arumugam K, Subramanian GS, Mallayasamy SR, Averineni RK, Reddy MS, Udupa N. A study of rivastigmine liposomes for delivery into the brain through intranasal route. Acta Pharm 2008; 58: 287-97.
28. Migliore MM, Vyas TK, Campbell RB, Amiji MM, Waszczak BL. Brain delivery of proteins by the intranasal route of administration: a comparison of cationic liposomes versus aqueous solution formulations. J Pharm Sci 2009; 99: 1745-61.
29. Tröster SD, Kreuter J. Influence of the surface properties of the low contact angle surfactants on the body distribution of 14C poly(methylmethacrylate) nanoparticles. J Microencapsul 1992; 9: 19-28.
30. Peracchia MT, Vauthier C, Desmaële D, Gulik A, Dedieu JC, Demoy M, et al. Pegylated nanoparticles from a novel methoxypolyethylene glycol cyanoacrylate-hexadecyl cyanoacrylate amphiphilic copolymer. Pharm Res 1998; 15: 550-6.
31. Kreuter J. Nanoparticulate systems for brain delivery of drugs. Adv Drug Deliv Rev 2001; 47: 65-81.
32. Kreuter J, Ramge P, Petrov V, Hamm S, Gelperino SE, Engelhardt B, et al. Direct evidence that polysorbate-80-coated poly(butylcyanoacrylate) nanoparticles deliver drugs of the CNS via specific mechanisms requiring prior binding of drug to the nanoparticles. Pharm Res 2003; 20: 409-16.
33. Kreuter J. Influence of the surface properties on nanoparticulatemediated transport of drugs to the brain. J Nanosci Nanotechnol 2004; 4: 484-8.
34. Michaelis K, Hoffmann MM, Dreis S, Herbert E, Alyautdin RN, Michaelis M, et al. Covalent linkage of apolipoprotein E to albumin nanoparticles strongly enhances drug transport into the brain. J Pharmacol Exp Ther 2006; 317: 1246-53.
35. Koziara JM, Lockman PR, Allen DD, Mumper RJ. Paclitaxel nanoparticles for the potential treatment of brain tumors. J Control Release 2004, 99: 259-69.
36. Reinhardt RR, Bondy CA. Insulin-like growth factors cross the blood-brain barrier. Endocrinology 1994; 135: 1753-61.
37. Golden PL, Maccagnan TJ, Pardridge WM. Human blood brain barrier leptin receptor. Binding and endocytosis in isolated human brain microvessels. J Clin Invest 1997; 99: 14-8.
38. Fishman JB, Rubin JB, Handrahan JV, Connor JR, Fine RE. Receptor-mediated transcytosis of transferrin across the bloodbrain barrier. J Neurosci Res 1987; 18: 299-304.
39. Ke W, Shao K, Huang R, Han L, Liu Y, Li J, et al. Gene delivery targeted to the brain using an Angiopep-conjugated polyethyleneglycol-modified polyamidoamine dendrimer. Biomaterials 2009; 30: 6976-85.
40. Zhang Y, Pardridge WM. Conjugation of brain-derived neurotrophic factor to a blood-brain barrier drug targeting system enables neuroprotection in regional brain ischemia following intravenous injection of the neurotrophin. Brain Res 2001; 889: 49-56.
41. Shi N, Pardridge WM. Noninvasive gene targeting to the brain. Proc Natl Acad Sci U S A 2000; 97: 7567-72.
42. Huang R-q, Ke W-l, Qu Y-h, Zhu J-h, Pei Y-y, Jiang C. Characterization of lactoferrin receptor in brain endothelial capillary cells and mouse brain. J Biomed Sci 2007; 14: 121-8.
43. Boado RJ, Zhang Y, Zhang Y, Pardridge WM. Humanization of anti-human insulin receptor antibody for drug targeting across the human blood-brain barrier. Biotechnol Bioeng 2006; 96: 381-391.
44. Bangham AD, Standish MM, Watkins JC. Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol 1965; 13: 238-52.
45. Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science 2004; 303: 1818-22.
46. Allen TM. Liposomes. Opportunities in drug delivery. Drugs 1997; 54(Suppl 4): 8-14.
47. Gregoriadis G. Homing of Liposomes to Target-Cells. Biochem Soc Trans 1975; 3: 613-8.
48. Torchilin VP. Liposomes as delivery agents for medical imaging. Mol Med Today 1996; 2: 242-9.
49. Shi N, Zhang Y, Zhu C, Boado RJ, Pardridge WM. Brain-specific expression of an exogenous gene after i.v. administration. Proc Natl Acad Sci U S A 2001; 98: 12754-9.
50. Xie Y, Ye L, Zhang X, Cui W, Lou J, Nagai T, et al. Transport of nerve growth factor encapsulated into liposomes across the bloodbrain barrier: in vitro and in vivo studies. J Control Release 2005; 105: 106-119.
51. Schnyder A, Krahenbuhl S, Drewe J, Huwyler J. Targeting of daunomycin using biotinylated immunoliposomes: pharmacokinetics, tissue distribution and in vitro pharmacological effects. J Drug Target 2005; 13: 325-35.
52. Afergan E, Epstein H, Dahan R, Koroukhov N, Rohekar K, Danenberg HD, et al. Delivery of serotonin to the brain by monocytes following phagocytosis of liposomes. J Control Release 2008; 132: 84-90.
53. Di Paolo D, Pastorino F, Brignole C, Marimpietri D, Loi M, Ponzoni M, et al. Drug delivery systems: application of liposomal antitumor agents to neuroectodermal cancer treatment. Tumori 2008; 94: 246-53.
54. Torchilin VP. Recent advances with liposomes as pharmaceutical carrier. Nat Rev Drug Discov 2005; 4; 145-60.
55. Barratt G. Therapeutic applications of colloidal drug carriers. Pharm Sci Technolo Today 2000; 3: 163-71.
56. Sihorkar V, Vyas SP. Polysaccharide coated liposomes for oral drug delivery: Development and characterization. In: Vyas SP, Dixit VK, editors. Advances in Liposomal Therapeutics. New Delhi: CBS Publishers; 2001.
57. Samad A, Sultana Y, Aqil M. Liposomal drug delivery systems: an update review. Curr Drug Deliv 2007; 4: 297-305.
58. Alexis F, Pridgen E, Molnar L, Farokhzad O. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharmacol 2008; 5: 505-15.
59. Couvreur P, Vauthier C. Nanotechnology: intelligent design to treat complex disease. Pharm Res 2006; 23: 1417-50.
60. Van Vlerken L, Vyas T, Amiji M. Poly(ethylene glycol)-modified nanocarriers for tumor-targeted and intracellular delivery. Pharm Res 2007; 24: 1405-14.
61. Peracchia MT, Fattal E, Desmaële D, Besnard M, Noël JP, Gomis JM, et al. Stealth PEGylated polycyanoacrylate nanoparticles for intravenous administration and splenic targeting. J Control Release 1999; 60: 121-8.
62. Panagi Z, Beletsi A, Evangelatos G, Livaniou E, Ithakissios D, Avgoustakis K. Effect of dose on the biodistribution and pharmacokinetics of PLGA and PLGA-mPEG nanoparticles. Int J Pharm 2001; 221: 143-52.
63. Gabizon A, Shmeeda H, Barenholz Y. Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies. Clin Pharmacokinet 2003; 42: 419-36.
64. Lee CM, Choi Y, Huh EJ, Lee KY, Song HC, Sun MJ, et al. Polyethylene glycol (PEG) modified 99mTc-HMPAO-liposome for improving blood circulation and biodistribution: the effect of the extent of PEGylation. Cancer Biother Radiopharm 2005; 20: 620-8.
65. Owens D, Peppas N. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm 2006; 307: 93-102.
66. Schnyder A, Huwyler J. Drug transport to brain with targeted liposomes. NeuroRx 2005; 2: 99-107.
67. Visser CC, Voorwinden LH, Harders LR, Eloualid M, van Bloois L, Crommelin DJA, et al. Coupling of Metal Containing Homing Devices to Liposomes via a Maleimide Linker: Use of TCEP to Stabilize Thiol-groups without Scavenging Metals. J Drug Target 2004; 12: 569-73.
68. Connor, J.R., Keil, R.L. Use of ferritin to treat iron deficiency disorders. US20090142360 (2009).
69. Connor, J.R., Keil, R.L. Use of ferritin to treat iron deficiency disorders. WO2009120168 (2009).
70. Gaillard, P.J. Conjugates for targeted drug delivery across the blood-brain barrier. EP2308514 (2011).
71. Smith GP. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface; Science 1985; 228: 1315-7.
72. van Rooy, I., Hennink, W.E., Mastrobattista, E., Schiffelers, R.M., Dinter-Heidorn, H., Brinkhuis, R.P., Van Hest, J., Rutjes, F.P.J.T. Peptide ligands for targeting to the blood-brain barrier. WO2011005098 (2011).
73. Lu, M.J.M., Liang, H.-F., Cheng, S.-M., Ko, Y.-J., Chang, L.-W. Peptide for transmigration across blood-brain barrier and delivery systems comprising the same. US20110165079 (2011).
74. Abulrob, A., Zhang, J. Targeted delivery of compounds using multimerization technology. WO2007036022 (2007).
75. Abulrob, A., Zhang, J. Targeted delivery of compounds using multimerization technology. US20090233357 (2009).
76. Qi, X. Fusogenic properties of saposin C and related proteins and peptides for application to transmembrane drug delivery system. US20090142267 (2009).
77. Qi, X. Fusogenic properties of saposin C and related proteins and peptides for application to transmembrane drug delivery system. WO2010053489 (2010).
78. Torchilin, V.P., Rammohan, R., Levchenko, T.S., Volodina, N. Intracellular delivery of therapeutic agents: WO2003068190 (2003).
79. Torchilin, V.P., Rammohan, R., Levchenko, T.S., Volodina, N. Intracellular delivery of therapeutic agents: US20050163832 (2005).
80. Frey, W.H., Thorne, R.G. Method for administering agents to the central nervous system. US7273618 (2007).
81. Giacca, M., Da Silva Filipe, A.C., De Magalhães Simões, S.P., Monteiro Pedroso De Lima, M.C. Nano-lipid-based carriers for targeted delivery of viral vectors and process for its production. WO2009053937 (2009).
82. Narasimhaswami, M., Shankar, P., Kumar, P. Method for delivery across the blood brain barrier. WO2008054544 (2008).
83. Narasimhaswami, M., Shankar, P., Kumar, P. Method for delivery across the blood brain barrier. US20100233084 (2010).
84. Kaemmerer, W.F. Devices, systems and methods for improving memory and/or cognitive function through brain delivery of siRNA. US20090060987 (2009).
85. Kaemmerer, W.F. Devices, systems and methods for improving memory and/or cognitive function through brain delivery of siRNA. US20100184835 (2010).
86. Hecker J.G., Nantz M. Novel methods and models for rapid, widespread delivery of genetic material to the CNS using non-viral, cationic lipid-mediated vectors. US20100249208 (2010).
87. Nair, M.P.N., Saiyed, Z.M. Magnetic nanodelivery of therapeutic agents across the blood brain barrier. WO2010025322 (2010).
88. Munson, J.M., Bellamkonda, R.W., Arbiser, J.L. Nanocarrier therapy for treating invasive tumors. WO2010124004 (2010).
89. Heldman, E., Linder, C., Grinberg, S., Kolot, V., Shaubi, E. Amphiphilic compounds and vesicles liposomes for organ-specified drug targeting. US7887833 (2011).
90. Haas, H., Riccio, P. Cationic colloidal carriers for delivery of active agents to the blood-brain barrier in the course of neuroinflammatory diseases. WO2008052766 (2008).
91. Haas, H., Riccio, P. Cationic colloidal carriers for delivery of active agents to the blood-brain barrier in the course of neuroinflammatory diseases. US20110002851 (2011).
92. Masserini, M., Re, F., Sesana, M.S. Liposomes capable of effectively binding the beta amyloid peptide. WO2009150686 (2009)
93. Masserini, M., Re, F., Sesana, M.S. Liposomes capable of effectively binding the beta amyloid peptide. US20110177158 (2011)
94. Torchilin, V.P., Musacchio, T. SiRNA phospholipid conjugate. WO2011008857 (2011).
95. Castaigne, J.-P., Demeule, M., Che, C., Regina, A. Compositions and methods for the transport of therapeutic agents. WO2011041897 (2007).
96. Shum P, Kim JM, Thompson DH. Phototriggering of liposomal drug delivery systems. Adv Drug Deliv Rev 2001; 53: 273-84.
97. Wieder ME, Hone DC, Cook MJ, Handsley MM, Gavrilovic J, Russell D. Intracellular photodynamic therapy with photosensitizer-nanoparticle conjugates: cancer therapy using a "Trojan horse. " Photochem Photobiol Sci 2006; 5: 727-34.
98. Needham D, Dewhirst MW. The development and testing of a new temperature-sensitive drug delivery system for the treatment of solid tumors. Adv Drug Deliv Rev 2001; 53: 285-305.
99. Ponce AM, Vujaskovic Z, Yuan F, Needham D, Dewhirst MW. Hyperthermia mediated liposomal drug delivery. Int J Hyperthermia 2006; 22: 205-13.
100. Babincová M, Cicmanec P, Altanerová V, Altaner C, Babinec P. AC-magnetic field controlled drug release from magnetoliposomes: design of a method for site-specific chemotherapy. Bioelectrochemistry 2002; 55: 17-9.
101. Puri A, Loomis K, Smith B, Lee J-H, Yavlovich A, Eli Heldman E, et al. Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic. Crit Rev Ther Drug Carrier Syst 2009; 26: 523-80.
102. Kong G, Braun RD, Dewhirst MW. Hyperthermia enables tumorspecific nanoparticle delivery: effect of particle size. Cancer Res 2000; 60: 4440-5.
103. Huwyler J, Wu D, Pardridge WM. Brain drug delivery of small molecules using immunoliposomes. Proc Natl Acad Sci U S A 1996; 93: 14164-9.
104. McNeeley KM, Annapragada A, Bellamkonda RV. Decreased circulation time offsets increased efficacy of PEGylated nanocarriers targeting folate receptors of glioma. Nanotechnology 2007; 18: 385101.
105. McNeeley KM, Karathanasis E, Annapragada AV, Bellamkonda RV. Masking and triggered unmasking of targeting ligands on nanocarriers to improve drug delivery to brain tumors. Biomaterials 2009; 30: 3986-95.
106. Ko YT, Bhattacharya R, Bickel U. Liposome encapsulated polyethylenimine/ODN polyplexes for brain targeting. J Control Release 2009; 133: 230-7.
107. Feng B, Tomizawa K, Michiue H, Miyatake S, Han XJ, Fujimura A et al. Delivery of sodium borocaptate to glioma cells using immunoliposome conjugated with anti-EGFR antibodies by ZZ-His. Biomaterials 2009; 30: 1746-55.
108. Kizelsztein P, Ovadia H, Garbuzenko O, Sigal A, Barenholz Y. Pegylated nanoliposomes remote-loaded with the antioxidant tempamine ameliorate experimental autoimmune encephalomyelitis. J Neuroimmunol 2009; 213: 20-5.
109. Grahn AY, Bankiewicz KS, Dugich-Djordjevic M, Bringas JR, Hadaczek P, Johnson GA et al. Non-PEGylated liposomes for convection-enhanced delivery of topotecan and gadodiamide in malignant glioma: initial experience. J Neurooncol 2009; 95: 185-97.
110. Artzner F, Zantl R, Radler JO. Lipid-DNA and lipid polyelectrolyte mesophases: structure and exchange kinetics. Cell Mol Biol 2000; 46: 967-78.
111. da Cruz MT, Simoes S, de Lima MC. Improving lipoplex mediated gene transfer into C6 glioma cells and primary neurons. Exp Neurol 2004; 187: 65-75.
112. Zhang Y, Calon F, Zhu C, Boado RJ, Pardridge WM. Intravenous nonviral gene therapy causes normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism. Hum Gene Ther 2003; 14: 1-12.
113. Cardoso AL, Costa P, de Almeida LP, Simoes S, Plesnila N, Culmsee C, et al. Tf-lipoplex-mediated c-Jun silencing improves neuronal survival following excitotoxic damage in vivo. J Control Release 2010; 142: 392-403.
114. Findeis MA. The role of amyloid beta peptide 42 in Alzheimer's disease. Pharmacol Ther 2007; 116: 266-86.
115. De Felice FG, Ferreira ST. Beta-amyloid production, aggregation, clearance as targets for therapy in Alzheimer's disease. Cell Mol Neurobiol 2002; 22: 545-63.
116. Greenberg SM, Grabowski T, Gurol ME, Skehan ME, Nandigam RN, Becker JA, et al. Detection of isolated cerebrovascular betaamyloid with Pittsburgh compound B. Ann Neurol 2008; 64: 587-91.
117. Look GC, Jerecic J, Cherbavaz DB, Pray TR, Breach JC, Crosier WJ, et al. Discovery of ADDL-targeting small molecule drugs for Alzheimer's disease. Curr Alzheimer Res 2007; 4: 562-7.
118. Matsuoka Y, Saito M, LaFrancois J, Gaynor K, Olm V, Wang L, et al. Novel therapeutic approach for the treatment of Alzheimer's disease by peripheral administration of agents with an affinity to beta-amyloid. J Neurosci 2003; 23: 29-33.
119. Re F, Cambianica I, Sesana S, Salvati E, Cagnotto A, Salmona M, et al. Functionalization with ApoE-derived peptides enhances the interaction with brain capillary endothelial cells of nanoliposomes binding amyloid-beta peptide. J Biotechnol 2011; doi:10.1016/j.jbiotec.2011.06.037
120. Re F, Cambianica I, Zona C, Sesana S, Gregori M, Rigolio R, et al. Functionalization of liposomes with ApoE-derived peptides at different density affects cellular uptake and drug transport across a blood-brain barrier model. Nanomedicine 2011; doi:10.1016/j.nano.2011.05.004
121. Ivri, Y. Intracochlear drug delivery to the central nervous system. WO2011019954 (2011).
122. Lasic DD. Mixed micelles in drug delivery. Nature 1992; 355: 279-80.
123. Elworthy PH, Florence AT, Macfarlane CB. Solubilization by Surface Active Agents. London: Chapman & Hall; 1968.
124. Attwood D, Florence AT. Surfactant Systems. London: Chapman & Hall; 1983.
125. Mittal KL, Lindman B. Surfactants in Solution. New York (NY): Plenum Publishing; 1991.
126. Jones M, Leroux J. Polymeric micelles: a new generation of colloidal drug carriers. Eur J Pharm Biopharm 1999; 48: 101-11.
127. Torchilin VP. Structure and design of polymeric surfactant based drug delivery systems. J Control Release 2001; 73: 137-72.
128. Kwon GS, Kataoka K. Block copolymer micelles as long circulating drug vehicles. Adv Drug Deliv Rev 1995; 16: 295-309.
129. Gaucher G, Dufresne MH, Sant VP, Kang N, Maysinger D, Leroux JC. Block copolymer micelles: preparation, characterization and application in drug delivery. J Control Release 2005; 109: 169-88.
130. Aliabadi HM, Lavasanifar A. Polymeric micelles for drug delivery. Expert Opin Drug Deliv 2006; 3: 139-62.
131. Kwon GS. Polymeric micelles for delivery of poorly watersoluble compounds. Crit Rev Ther Drug Carr Syst 2003; 20: 357-403.
132. Torchilin VP, Levchenko TS, Whiteman KR, Yaroslavov AA, Tsatsakis AM, Rizos AK, et al. Amphiphilic poly-nvinylpyrrolidones: synthesis, properties and liposome surface modification. Biomaterials 2001; 22: 3035-44.
133. Le Garrec D, Taillefer J, Van Lier JE, Lenaerts V, Leroux JC. Optimizing pH-responsive polymeric micelles for drug delivery in a cancer photodynamic therapy model. J Drug Target 2002; 10: 429-37.
134. Kabanov AV, Chekhonin VP, Alakhov V, Batrakova EV, Lebedev AS, Melik-Nubarov NS, et al. The neuroleptic activity of haloperidol increases after its solubilization in surfactant micelles. Micelles as microcontainers for drug targeting. FEBS Lett 1989; 258: 343-5.
135. Miller DW, Batrakova EV, Waltner TO, Alakhov VY, Kabanov AV. Interactions of pluronic block copolymers with brain microvessel endothelial cells: evidence of two potential pathways for drug absorption. Bioconjug Chem 1997; 8: 649-57.
136. Katayose S, Kataoka K. Remarkable increase in nuclease resistance of plasmid DNA through supramolecular assembly with poly(ethylene glycol)-poly(L-lysine) block copolymer. J Pharm Sci 1998; 87: 160-3.
137. Trubetskoy VS, Gazelle GS, Wolf GL, Torchilin VP. Blockcopolymer of polyethylene glycol and polylysine as a carrier of organic iodine: design of long-circulating particulate contrast medium for x-ray computed tomography. J Drug Target 1997; 4: 381-8.
138. Yokoyama M, Miyauchi M, Yamada N, Okano T, Sakurai Y, Kataoka K, et al. Characterization and anticancer activity of the micelle-forming polymeric anticancer drug adriamycin-conjugated poly(ethylene glycol)-poly(aspartic acid) block copolymer. Cancer Res 1990; 50: 1693-700.
139. Harada A, Kataoka K. Novel polyion complex micelles entrapping enzyme molecules in the core. Preparation of narrowly-distributed micelles from lysozyme and poly(ethylene glycol)-poly(aspartic acid) block copolymer in aqueous medium. Macromolecules 1998; 31: 288-94.
140. Kwon GS, Naito M, Yokoyama M, Okano T, Sakurai Y, Kataoka K. Physical entrapment of adriamycin in AB block copolymer micelles. Pharm Res 1995; 12: 192-5.
141. Kwon GS, Naito M, Yokoyama M, Okano T, Sakurai Y, Kataoka K. Block copolymer micelles for drug delivery: loading and release of doxorubicin. J Control Release 1997; 48: 195-201.
142. Jeong YI, Cheon JB, Kim SH, Nah JW, Lee YM, Sung YK, et al. Clonazepam release from core-shell type nanoparticles in vitro. J Control Release 1998; 51: 169-78.
143. Kim SY, Shin IG, Lee YM, Cho CG, Sung YK. Metoxy poly(ethylene glycol) and (-caprolactone amphiphilic block copolymeric micelle containing indomethacin. II. Micelle formation and drug release behaviors. J Control Release 1998; 51: 13-22.
144. Allen C, Yu Y, Maysinger D, Eisenberg A. Polycaprolactone-bpoly(ethylene oxide) block copolymer micelles as a novel drug delivery vehicle for neurotrophic agents FK506 and L-685,818. Bioconjug Chem 1998; 9: 564-72.
145. Hagan SA, Coombes AGA, Garnett MC. Polylactide-poly(ethylene glycol) copolymers as drug delivery systems. 1. Characterization of water dispersible micelle-forming systems. Langmuir 1996; 12: 2153-61.
146. Ramaswamy M, Zhang X, Burt H, Wasan KM. Human plasma distribution of free paclitaxel and paclitaxel associated with diblock copolymers. J Pharm Sci 1997; 86: 460-4.
147. Kabanov AV, Kabanov VA. Interpolyelectrolyte and block ionomer complexes for gene delivery: physico-chemical aspects. Adv Drug Deliv Rev 1990; 30: 49-60.
148. Trubetskoy VS, Torchilin VP. Polyethyleneglycol based micelles as carriers of therapeutic and diagnostic agents. STP Pharma Sci 1996; 6: 79-86.
149. Torchilin VP. Lipid-core micelles for targeted drug delivery. Curr Drug Deliv 2005; 2: 319-27.
150. Torchilin VP. Lipid-based parenteral drug delivery systems: biological implications. In: Wasan K, editor. Role of lipid excipients in modifying oral and parenteral drug delivery. Hoboken (NJ): John Wiley & Sons; 2007.
151. Torchilin VP. Micellar nanocarriers: pharmaceutical perspectives. Pharm Res 2007; 24: 1-16.
152. Lukyanov AN, Torchilin VP. Micelles from lipid derivatives of watersoluble polymers as delivery systems for poorly soluble drugs. Adv Drug Del Rev 2004; 56: 1273-89.
153. Torchilin VP, Lukyanov AN, Gao Z, Papahadjopoulos-Sternberg B. Immunomicelles: targeted pharmaceutical carriers for poorly soluble drugs. Proc Natl Acad Sci U S A 2003; 100: 6039-44.
154. Onyuksel, H., Rubinstein, I. Materials and methods for making improved micelle compositions. US20110142884 (2011)
155. Onyuksel, H., Rubinstein, I. Materials and methods for making improvred micelle compositions. EP1146857 (2005).
156. Torchilin, V.P., Lukyanov, A.S., Gao, Z. Micelle delivery system loaded with a pharmaceutical agent. WO2004098569 (2004).
157. Torchilin, V.P., Lukyanov, A.S., Gao, Z. Micelle delivery system loaded with a pharmaceutical agent. US20060216342 (2006).
158. Torchilin, V.P., Sawant, R., Kale, A. Condition-dependent, multiple target delivery system: US20080031883 (2008).
159. Onyuksel, H., Rubinstein, I. Hydrophilic polymer-conjugated lipids for peptide and protein folding disorders: WO2008054498 (2008).
160. Onyuksel, H., Rubinstein, I. Hydrophilic polymer-conjugated lipids for peptide and protein folding disorders: US20100062969 (2010).
161. Ko, Y.T., Kale, A., Torchilin, V.P. Self assembling micelle-like nanoparticles for systemic gene delivery: WO2009061515 (2009).
162. Ko, Y.T., Kale, A., Torchilin, V.P. Self assembling micelle-like nanoparticles for systemic gene delivery: US20100285111 (2010).
163. Sailor, M.J., Bhatia, S.N., Rouslahti, E., Park, J.H., Von Maltzahn, G.A. Method for preparation of micellar hybrid nanoparticles for therapeutic and diagnostic applications and composition thereof. WO2010008876 (2010).
164. Torchilin, V.P., Levchenko, T.S. Mixed micelles including amphipatic conjugates of RNA agents, and uses thereof: WO2009009025 (2009).
165. Torchilin, V.P., Levchenko, T.S. Mixed micelles including amphipatic conjugates of RNA agents, and uses thereof: US20110008395 (2011).
166. Torchilin VP, Levchenko TS, Lukyanov AN, Khaw BA, Klibanov AL, Rammohan R, et al. p-Nitrophenylcarbonyl-PEG-PEliposomes: fast and simple attachment of specific ligands including monoclonal antibodies, to distal ends of PEG chains via pnitrophenylcarbonyl groups. Biochim Biophys Acta 2001; 1511: 397-411.
167. Salmaso S, Pappalardo JS, Sawant RR, Musacchio T, Rockwell K, Caliceti P, et al. Targeting glioma cells in vitro with ascorbateconjugated pharmaceutical nanocarriers. Bioconjug Chem 2009; 20: 2348-55.
168. Torchilin VP, Rammohan R, Weissig V, Levchenko TS. TAT peptide on the surface of liposomes affords their efficient intracellular delivery even at low temperature and in the presence of metabolic inhibitors. Proc Natl Acad Sci U S A 2001; 98: 8786-91.
169. Ko YT, Kale A, Hartner WC, Papahadjopoulos-Sternberg B, Torchilin VP. Self-assembling micelle-like nanoparticles based on phospholipid-polyethyleneimine conjugates for systemic gene delivery. J Control Release 2009; 133: 132-8.
170. Musacchio T, Vaze O, D'Souza G, Torchilin VP. Effective stabilization and delivery of siRNA: reversible siRNA-phospholipid conjugate in nanosized mixed polymeric micelles. Bioconjug Chem 2010; 21: 1530-6.
171. Pai AS, Rubinstein I, Onyuksel H. PEGylated phospholipid nanomicelles interact with α amyloid(1-42) and mitigate its α-sheet formation, aggregation and neurotoxicity in vitro. Peptides 2006; 27: 2858-66.
172. Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE. Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release 2001; 70: 1-20.
173. Letchford K, Burt H. A review of the formation and classification of amphiphilic block copolymer nanoparticulate structures: micelles, nanospheres, nanocapsules and polymersomes. Eur J Pharm Biopharm 2007; 65: 259-69.
174. Heurtault B, Saulnier P, Pech B, Proust J-E, Benoit J-P. A Novel phase inversion-based process for the preparation of lipid nanocarriers. Pharm Res 2002; 19: 875-80.
175. Heurtault, B., Saulnier, P., Pech, B., Proust, J.E., Richard, J., Benoit, J.P. Lipidic nanocapsules: preparation process and use as Drug Delivery Systems. WO02688000 (2000).
176. Huynh NT, Passirani C, Saulnier P, Benoit JP. Lipid nanocapsules: A new platform for nanomedicine. Int J Pharm 2009; 379: 201-9.
177. Saulnier, P., Benoit, J.P., Anton, N. Nanocapsules with liquid lipidic core loaded with water soluble or water dispersible ingredient(s). WO2009001019 (2009).
178. Saulnier, P., Benoit, J.P., Anton, N. Nanocapsules with liquid lipidic core loaded with water soluble or water dispersible ingredient(s). US20100266676 (2010).
179. Saulnier, P., Benoit, J.P., Anton, N. Method for preparing lipid nanoparticles. WO2009004214 (2009).
180. Saulnier, P., Benoit, J.P., Anton, N. Method for preparing lipid nanoparticles. US2010023275 (2010).
181. Roger, E., Lagarce, F., Benoit, J.P. Lipid nanocapules, method for preparing same, and use thereof as a drug. WO2011036234 (2011).
182. Heurtault, B., Saulnier, P., Benoit, J.P., Proust, J.E., Pech, B., Joel, R. Lipid nanocapsules, preparation process and use as medicine. US20090238865 (2009).
183. Benoit, J.P., Pitard, B., Saulnier, P., Passirani, C., Lambert, O., Vonarbourg, A. Nanocapsules of lipophilic complexes of nucleic acids. WO2008096321 (2008).
184. Anton, N., Saulnier, P., Benoit, J.P. Aqueous-core lipid nanocapsules for encapsulating hydrophilic and/or lipophilic molecules. WO2009037310 (2009).
185. Anton, N., Saulnier, P., Benoit, J.P. Aqueous-core lipid nanocapsules for encapsulating hydrophilic and/or lipophilic molecules. US20100297247 (2010).
186. Benoit, J.P., Perrier, T. Method for preparing functionalized lipid capsules. WO2010113111 (2010)
187. Beduneau A, Saulnier P, Hindre F, Clavreul A, Leroux JC, Benoit JP. Design of targeted lipid nanocapsules by conjugation of whole antibodies and antibody Fab' fragments. Biomaterials 2007; 28: 4978-90.
188. Beduneau A, Hindre F, Clavreul A, Leroux JC, Saulnier P, Benoit JP. Brain targeting using novel lipid nanovectors. J Control Release 2008; 126: 44-9.
189. Vonarbourg A, Passirani C, Desigaux L, Allard E, Saulnier P, Lambert O, et al. The encapsulation of DNA molecules within biomimetic lipid nanocapsules. Biomaterials 2009; 30: 3197-204.
190. Morille M, Passirani C, Letrou-Bonneval E, Benoit JP, Pitard B. Galactosylated DNA lipid nanocapsules for an efficient hepatocyte targeting. Int J Pharm 2009; 379: 293-300.
191. Jagger C, Gillies C, Moscone F, Cambois E, Van Oyen H, Nusselder W, et al. Inequalities in healthy life years in the 25 countries of the European Union in 2005: a cross-national meta-regression analysis. Lancet 2008; 372: 2124-31.
192. Joshi MD, Müller RH. Lipid nanoparticles for parenteral delivery of actives. Eur J Pharm Biopharm 2009. 71: 161-72.